Fast Forward℠

Who We Are

- An integral part of the National Multiple Sclerosis Society's comprehensive approach to MS research and treatment, founded in 2007 as a not for profit organization, focused on speeding promising research discoveries into commercial drug development

What We Do

- Accelerate the development of research discoveries into new or improved MS therapies, through collaboration and funding support across university-based research, biotechnology and pharmaceutical companies

Leadership Team

- Peter Tarricone, Board Chair
- Cynthia Zagieboylo, CEO
- Timothy Coetzee, PhD, President

Our Advisors

- World class MS clinicians
- Leading MS researchers from top-tier academic institutions in US and abroad
- Business development professionals and venture capitalists
- CEOs, COOs, and Research Heads from biotechnology companies
- Corporate and Intellectual Property attorneys

Financial Goal

- Raise and deploy $60 million by 2012 through two funding streams; General Fund of $30 million, and a Collaborative Fund of $30 million

Our Strategy

- Provide leveraged funding to seed early-stage companies and academic groups preparing to start a company or license technology, bridging the gap between promising discoveries and pre-clinical development necessary to begin clinical trials
- Source and evaluate opportunities worldwide through a combination of proven National MS Society research processes and strategic business return processes, facilitating faster entry into clinical trials

Funding Criteria

- Innovative therapies, diagnostics, or medical devices
- A compelling scientific/clinical case with a reasonable path to approval
- Intellectual property secured
- Additional capital on hand or committed
- A strong management team

Our Vision

- A world free of MS

Our Objective

- To speed treatments to people with MS, faster